This site uses optional cookies which are currently not set, but will be if you visit another page. Find out more about the cookies we use

Cobra and Tecrea Awarded £112K Innovate UK Grant to Develop AAV Scalable Production Bioprocess

2 April 2015

Cobra Biologics and Tecrea, a cell delivery biotechnology company, have been awarded a 15 month collaborative grant of £112,291 ($166,000 USD) by the UK’s innovation agency, Innovate UK for the development of a scalable Adeno Associated Virus (AAV) production bioprocess.

The grant is awarded under Innovate UK’s ‘Technology Inspired Innovation’ competition, which aims to stimulate innovation within biosciences, identified by UK government as one of four key enabling technology areas.

The collaboration between Cobra and Tecrea focuses on the development of a robust, large scale bioprocess for AAV production. AAV is a safe and effective gene therapy vector with a growing commercial demand that cannot be met by current, non-scalable production approaches. The new system aims to achieve scalable GMP production of AAV at low cost by combining NanoCargo™, an efficient, low toxicity nanoparticle-based transfection system from Tecrea with Cobra’s small footprint hollow fibre bioreactors and manufacturing expertise.

Dr Daniel Smith, CSO Cobra Biologics, commented: “We are looking forward to collaborating closely with Tecrea, and their innovative delivery system. This is a very exciting project for Cobra, as it has the potential to expand our current viral production offering for AAV, providing a scalable route for viral vector production using a transient transfection approach.”

Dr John Ridden, Director at Tecrea, said: “We are delighted to be working with Cobra Biologics on this project. This grant is a great opportunity for us to move our exciting nanotechnology delivery platform into large-scale transfection, which in turn could result in significant improvements in the production of new therapies.”

About Tecrea
Tecrea Ltd is a privately held, newly formed UK registered company located within the London Bioscience Innovation Centre (LBIC). We are a small and independently owned biotechnology company. Our mission is to provide vastly improved cell delivery technology for research and the clinic. We have developed a line of NanoCargo™ products, which can be used to improve the delivery of a range of molecules into cells, including nucleic acids. NanoCargo™ is based on a novel nanotechnology, which may sound complicated, but our methods make it easy. We believe strongly that cell delivery technology should be effectively non-toxic to ensure experimental integrity and enable clinical progression. Tecrea is developing products that are uniquely non-toxic and effective for your transfection applications. For more information, visit:

About Innovate UK
Innovate UK is the new name for the Technology Strategy Board – the UK’s innovation agency. Taking a new idea to market is a challenge. Innovate UK funds, supports and connects innovative businesses through a unique mix of people and programmes to accelerate sustainable economic growth. For further information visit:

Cobra Tecrea 2.jpg